OMB APPROVAL
       OMB Number: 3235-0058
   UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Expires: August 31, 2015
 Estimated average burden
       hours per response.......2.50
       
  FORM 12b-25  SEC FILE NUMBER
 
000-29819
       
       CUSIP NUMBER
   NOTIFICATION OF LATE FILING
019621101
 
 
 
 
(Check one): þ  Form 10-K o  Form 20-F o  Form 11-K o  Form 10-Q o  Form 10-D o  Form N-SAR o  Form N-CSR
                                                                                                                                                                                                                                                                                              
                             
      For Period Ended:   December 31, 2012
       
         
   o  Transition Report on Form 10-K
         
   o  Transition Report on Form 20-F
         
   o  Transition Report on Form 11-K
         
   o  Transition Report on Form 10-Q
         
   o  Transition Report on Form N-SAR
         
      For the Transition Period Ended:
                      
 
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

Alliqua, Inc.
 
Full Name of Registrant
 
Hepalife Technologies, Inc.  
Former Name if Applicable
 
850 Third Avenue, Suite 1801
 
Address of Principal Executive Office (Street and Number)
 
New York, New York 10022
 
City, State and Zip Code
 
 


 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)
 
 
   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
     
þ  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
   (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
     
 
PART III – NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
 
 
Alliqua, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2012 (the “Form 10-K”) due to the Company’s change in management in February 2013 and the need for new management to fully review, understand and revise the Company’s disclosures as necessary.  The Company expects to file the Form 10-K within the period described under Rule 12b-25(b)(2).
 
 
 
PART IV — OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification
 
 
Steven Berger
   (646)  
218-1450
 
(Name)
 
(Area Code)
 
(Telephone Number)
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes 
þ
No 
o  
   
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes 
o
No 
þ  
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
 
 
 
2

 
 
   Alliqua, Inc.
 
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  April 1, 2013
   
By:
/s/ Steven Berger
      Name:
Steven Berger
      Title:
Chief Financial Officer

 
3